Skip to main content

Table 4 The association between frailty category and clinical outcomes

From: Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial

  Hazard ratio (95% CI)
Fit Pre-frail Mild-moderate frailty Severe frailty
Primary endpoints
 Time to first adjudicated stroke or systemic embolism
  Unadjusted 1 1.22 (1.03–1.45) 1.93 (1.59–2.35) 1.58 (0.99–2.55)
  Adjusted 1 1.22 (0.90–1.65) 1.84 (1.31–2.59) 2.30 (1.17–4.52)
 Time to adjudicated major bleeding during treatment
  Unadjusted 1 1.22 (1.04–1.43) 1.75 (1.46–2.09) 3.02 (2.17–4.20)
  Adjusted 1 1.32 (1.04–1.68) 1.79 (1.36–2.37) 2.86 (1.72–4.76)
Composite net clinical endpoints
 Stroke, systemic embolic event, major bleeding, or death
  Unadjusted 1 1.30 (1.19–1.43) 2.31 (2.09–2.55) 3.29 (2.74–3.96)
  Adjusted 1 1.49 (1.28–1.74) 2.45 (2.07–2.90) 3.56 (2.63–4.81)
 Disabling stroke, life-threatening bleeding, or death
  Unadjusted 1 1.37 (1.22–1.53) 2.60 (2.30–2.94) 3.69 (2.96–4.59)
  Adjusted 1 1.60 (1.32–1.95) 2.88 (2.33–3.55) 4.59 (3.24–6.50)
 Stroke, systemic embolic event, life-threatening bleeding, or death
  Unadjusted 1 1.32 (1.19–1.47) 2.49 (2.22–2.78) 3.36 (2.73–4.14)
  Adjusted 1 1.56 (1.30–1.87) 2.73 (2.24–3.33) 4.24 (3.04–5.91)
Death
 Unadjusted 1 1.40 (1.24–1.58) 2.75 (2.41–3.13) 3.94 (3.13–4.97)
 Adjusted 1 1.68 (1.36–2.09) 3.13 (2.48–3.95) 4.97 (3.42–7.23)
  1. Adjustments made for sex, age, race, and region. Interaction by treatment group: not significant